IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
**Review Article**
February 2023 Vol.:26, Issue:3


# Detailed Drug Information on Etoposide: A Comprehensive Guide

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

**[1]Prajwal Waman Ghatol, [1]R Shivani, [1]Kreena D Parmar, [2*]S P Srinivas Nayak**

*[1]Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760*

*[2]Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy and Research. Parul University, Vadodara, Gujarat, India, 391760.*

**Submitted:** 23 January 2023
**Accepted:** 02 February 2023
**Published:** 28 February 2023

**Keywords:** Etoposide, Cancer, Topoisomerase II inhibitor, HLA, Hodgkin's disease, Non-Hodgkin lymphoma, Ewing's sarcoma.

**ABSTRACT**

Etoposide is a chemotherapy drug that is used in the treatment of various types of cancer, including testicular, ovarian, lung, and gastric cancer. This powerful chemotherapy drug is known for its ability to target rapidly dividing cells and stop the growth of cancerous tumors. However, as with any medication, it is important to have a thorough understanding of the pharmacokinetics and pharmacodynamics of the drug, as well as its potential drug interactions, adverse drug reactions, and indications for use. In this article, we will explore these topics in detail, providing you with the information you need to understand the full spectrum of the drug.

HUMAN JOURNALS
www.ijppr.humanjournals.com

## 1. INTRODUCTION:

Etoposide is a semi-synthetic derivative of podophyllotoxin, a naturally occurring substance that is extracted from the mayapple plant. Etoposide is a medication used in the management and treatment of various cancers such as testicular, prostate, bladder, stomach, and lung cancer. It is in the topoisomerase II inhibitor class of medications. This activity outlines the indications, action, and contraindications for etoposide as a valuable agent in managing various cancers listed above, Hodgkin and non-Hodgkin lymphoma and brain tumors. (And other disorders when applicable)[1]. Etoposide is inactive against malignant melanoma, colorectal cancer, and cancer of the head and neck [1]. Although etoposide has been widely and successfully used to treat many types of cancer, patients treated with etoposide may develop secondary leukemia. Due to the increases in the overall cure rate of patients, interest has arisen on the adverse effects, and special attention has been focused on the potential risk of therapy-related secondary leukemia [2,3].

## 2. PHARMACOKINETICS OF ETOPOSIDE:

The pharmacokinetics of etoposide refer to the way the drug is absorbed, metabolized, and excreted by the body. The chemical stability of the anticancer drug etoposide in aqueous solution has been investigated utilizing a stability-indicating reversed-phase high-performance liquid Chromatographic assay with ultraviolet detection. The degradation processes can adequately be described by pseudo-first order kinetics [4].

**A: Absorption of Etoposide**: Etoposide is administered intravenously, which means that it is given directly into the bloodstream through an IV. IV administration of etoposide holds several advantages. The ability of etoposide to exert its topoisomerase inhibitory effect is directly correlated to the concentration and duration of etoposide in the blood. IV formulations allow for a higher bioavailability of a drug in the blood stream and therefore have been seen as the preferred route of administration but this also comes with disadvantages such as long hospital stays and elevated costs for hospitals as well as impact on patients' quality of life. Another disadvantage with IV administration is the use of solvents that are toxic upon repeated administration [5]. Oral etoposide is an alternative still being debated. Concerns of using oral etoposide include the decreased bioavailability, inter- and intra-patient variability as well as for the risk of decreased patient compliance. Most

studies show a bioavailability of etoposide ranging between 30 and 76% with a nonlinear absorption that decreases in bioavailability with increased dosage[5].

**B: Digestion of Etoposide:** When etoposide is given intravenously, it does not undergo any digestion before it is absorbed into the bloodstream. The drug is not metabolized in the gastrointestinal tract and does not undergo any first-pass metabolism in the liver, which means that the drug is rapidly and efficiently absorbed into the bloodstream.

**C: Metabolism of Etoposide**: Etoposide metabolism is primarily regulated by CYP3A4/5 enzymes and can also be modified by xenobiotics such as dexamethasone and rifampicin. The drug can be converted to active metabolites by prostaglandin synthases or myeloperoxidase, and inactivated by glutathione and glucuronide conjugation. The transport of etoposide and its conjugates is associated with ABCC1, ABCC3, and ABCB1. Although etoposide is a highly effective anticancer agent, it can cause delayed toxicity in the form of treatment-related acute myeloid leukemia or myelodysplastic syndrome, which has been linked to drug-induced formation of MLL fusion genes. The antitumor activity of etoposide is primarily delivered through inhibition of topoisomerase II alpha, while its carcinogenic effect is attributed to the beta isoform. Recent genetic studies have identified 64 variants contributing to etoposide-induced cytotoxicity [6].

**D: Excretion of Etoposide** Etoposide (oral) clearance is mostly influenced by glomerular filtration rate, and indirectly by ageing. The relationship between age and creatinine clearance has been widely reported. However, data shows that dose adjustment based on creatinine clearance would have a marginal impact on interpatient variability, reducing exposure variability from 25 to 18%. A dose reduction of 25% would theoretically be required in patient with severe renal failure. Renal function remains the only known factor that must be taken into account for etoposide dosing [7].

## 3. PHARMACODYNAMICS OF ETOPOSIDE:

The pharmacodynamics of etoposide refer to the way the drug interacts with the body and its target cells. Etoposide is an anticancer drug that targets DNA topoisomerase II (TopoII).

Topoisomerases are enzymes that regulate the topology of DNA by introducing temporary breaks in the DNA molecule. They are involved in various biological processes such as DNA replication, transcription, DNA repair, and chromatin remodeling. Topoisomerases are

divided into two types: type I and type II. Type I topoisomerases introduce single-stranded breaks, while type II topoisomerases introduce double-stranded breaks. The covalent bond formed between the tyrosine in the active site of the enzyme and the phosphate in the backbone of the DNA molecule is referred to as the cleavable or cleavage complex, which is a short-lived intermediate in the reaction. However, certain compounds can stabilize the cleavable complex, leading to the production of protein-associated breaks in the genome, which are toxic to the cell. The drug inhibits the re-ligation step of the TopoII reaction, leading to the stabilization of the cleavable complex, a short-lived intermediate in the TopoII reaction. The high-resolution structure of the ternary complex between TopoII, DNA, and etoposide has shown that specific interactions with amino acids of the enzyme are crucial for the drug to enter the TopoII-DNA complex. The drug also has a high affinity for chromatin and histones, particularly H1, suggesting that chromatin may be a target of the drug in addition to TopoII [8].

## 4. DRUG INTERACTIONS AND CONTRAINDICATIONS:

Patients on warfarin require close monitoring when using etoposide because of the potential side effects of bleeding [1]. Etoposide is relatively contraindicated during breastfeeding. Breastfeeding can resume after at least 24 hours after 80 mg/m^2 or less dosage of etoposide. This limitation is because it appears that chemotherapy can alter the normal microbiome and chemical make-up of breastmilk, adversely limiting the nutrients necessary for proper development in a baby [9]. The interaction of celecoxib with etoposide, cisplatin and 5-FU was shown to be dependent on the cancer cell line employed, the drug type used and the incubation schedule. The combination of celecoxib and the same antitumour drug also exerted different effects on different cell lines [10].

## 5. ADVERSE DRUG REACTIONS (ADRs):

Etoposide is a relatively well-tolerated chemotherapeutic agent [1]. But like all medications; etoposide can cause a range of adverse drug reactions (ADRs) which commonly include hair loss and gastrointestinal problems such as nausea, vomiting, and inflammation of the mouth [11]. Additionally, the severity of gastrointestinal toxicity can be mitigated with the use of antiemetic therapy. Alopecia becomes a more likely side effect at higher doses, with hair loss becoming universal at doses of 500 mg/m^2 or higher. The main dose-limiting side effect of etoposide is myelosuppression [12]. In some cases, patients may experience acute

hypersensitivity reactions during intravenous administration, which can cause flushing, bronchospasm, cyanosis, hypertension, or hypotension. These symptoms typically resolve within minutes after discontinuing the administration of etoposide. If a patient has previously experienced a hypersensitivity reaction, it is possible to safely re-administer the drug with premedication with corticosteroids and antihistamines [12]. Resistance to etoposide can occur due to several mechanisms, including cells with low levels of topoisomerase II and the presence of the multiple drug resistance efflux pump, which removes etoposide from cells. Some malignant cells may also have deactivated the drug [12].

## 6. INDICATIONS:

Etoposide is a chemotherapy medication that is primarily used for the treatment of a range of cancers, including testicular cancer, lung cancer, and ovarian cancer. The combination of carboplatin and etoposide has demonstrated efficacy in the treatment of small cell lung cancer, as seen in phase II clinical trials where it appears to be similarly effective as the combination of cisplatin and etoposide. Additionally, carboplatin/etoposide has been found to have a more favorable toxicity profile compared to cisplatin/etoposide when used in the treatment of non-small cell lung cancer. The combination is well-tolerated by elderly patients, and it lacks significant non-hematologic adverse effects. This favorable safety profile has prompted the exploration of dose escalation strategies using colony-stimulating factors and autologous bone marrow transplantation[3].However, the drug has also been used in the treatment of other diseases and syndromes, including hematologic disorders such as hemophagocytic lymphohistiocytosis (HLH).The biology of the remarkably beneficial effects of etoposide in HLH, previously not well understood, may be explained by the recent findings that FHL is associated with a defective triggering of apoptosis, and that etoposide is known to be an excellent initiator of apoptosis [13,14].The broad activity of etoposide across several histologic subtypes of malignant lymphoma and Hodgkin's disease indicates a potential that is only now being fully exploited. Used according to optimal doses and schedules, etoposide has single-agent activity that rivals earlier drugs such as the alkylating agents and doxorubicin [15].Etoposide has become one of the most active drugs for the treatment of non-Hodgkin's lymphoma, its optimal use remains to be determined. Nevertheless, it has been used judiciously in a wide variety of treatment settings, including management of aggressive non-Hodgkin's lymphoma, in combinations testing an aggressive

approach for the treatment of advanced indolent lymphomas, integrated combined-modality therapy for localized aggressive lymphoma, salvage therapy, and induction regimens with autologous bone marrow transplantation [16].A new drug combination, if osfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after standard therapy. The addition of if osfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone [17]. Carboplatin, etoposide, and bleomycin (JEB) in children with malignant extracranial germ cell tumors (GCTs) with conservative surgery, and a watch-and-wait approach after complete excision produced high cure rates and few serious complications [18].

## 7. CONCLUSION:

Etoposide is a potent chemotherapy drug that is used to treat a range of cancers. It works by disrupting the function of DNA, causing cancer cells to die. As with all chemotherapy drugs, it can cause a range of side effects and interactions with other medications. It is important to discuss all medications and treatments being taken with a healthcare professional before starting treatment with etoposide. Etoposide has also been used in the treatment of hematologic disorders, such as hemophagocytic lymphohistiocytosis (HLH) and other diseases and syndromes like Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Ewing's sarcoma and Germ cell tumors. Overall, etoposide is an important tool in the treatment of cancer, offering a range of benefits for patients. With proper management and monitoring, etoposide can be a highly effective and well-tolerant.

## 8. REFERENCES:

1. Reyhanoglu G, Tadi P. Etoposide. [Updated 2022 Jul 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
2. Wenchao Zhang, Panhong Gou, Jean-Marie Dupret, Christine Chomienne, Fernando Rodrigues-Lima,Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play,TranslationalOncology,Volume 14, Issue 10,2021,101169,ISSN 1936-5233,https://doi.org/10.1016/j.tranon.2021.101169.
3. Bishop J, F: Carboplatin/Etoposide in Small Cell Lung Cancer. Oncology 1992;49(suppl 1):11-18. doi: 10.1159/000227105
4. J.H. Beijnen, J.J.M. Holthuis, H.G. Kerkdijk, O.A.G.J. van der Houwen, A.C.A. Paalman, A. Bult, W.J.M. Underberg, Degradation kinetics of etoposide in aqueous solution, International Journal of Pharmaceutics,Volume 41, Issues 1–2,1988,Pages 169-178,ISSN 0378-5173,https://doi.org/10.1016/0378-5173(88)90149-4.

5. Ali, A.S., Grönberg, M., Langer, S.W. *et al.* Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). *Med Oncol* **35**, 47 (2018). https://doi.org/10.1007/s12032-018-1103-x
6. Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB. Etoposide pathway. Pharmacogenet Genomics. 2009 Jul;19(7):552-3. doi: 10.1097/FPC.0b013e32832e0e7f. PMID: 19512958; PMCID: PMC4164627.
7. Toffoli G, Corona G, Sorio R, Robieux I, Basso B, Colussi AM, Boiocchi M. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol. 2001 Nov;52(5):511-9. doi: 10.1046/j.0306-5251.2001.01468.x. PMID: 11736859; PMCID: PMC2014597.
8. Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J. 2015 Jan 19;14:95-108. doi: 10.17179/excli2015-561. PMID: 26600742; PMCID: PMC4652635.
9. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Etoposide. 2021 Jan 18. PMID: 29999703.
10. Hiľovská L, Jendželovský R, Fedoročko P. Potency of non-steroidal anti-inflammatory drugs in chemotherapy. Mol Clin Oncol. 2015 Jan;3(1):3-12. doi: 10.3892/mco.2014.446. Epub 2014 Oct 16. PMID: 25469262; PMCID: PMC4251142.
11. Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy. 1984 Mar-Apr;4(2):61-73.
12. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol. 1995 Apr;6(4):325-41.
13. Fadeel B, Orrenius S, Henter JI. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocyticlymphohistiocytosis patients. Br J Haematol. 1999 Aug;106(2):406-15. doi: 10.1046/j.1365-2141.1999.01538.x. PMID: 10460599.
14. Fadeel B, Orrenius S, Henter JI. Familial hemophagocytic lymphohistiocytosis: too little cell death can seriously damage your health. Leuk Lymphoma. 2001 Jun;42(1-2):13-20. doi: 10.3109/10428190109097672. PMID: 11699200.
15. O'Reilly SE, Klimo P, Connors JM. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer. 1991 Jan 1;67(1 Suppl):271-80. doi: 10.1002/1097-0142(19910101)67:1+<271::aid-cncr2820671311>3.0.co;2-l. PMID: 1984827.
16. Young RC. Etoposide in the treatment of non-Hodgkin's lymphomas. Semin Oncol. 1992 Dec;19(6 Suppl 13):19-25. PMID: 1492224.
17. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 20;348(8):694-701. doi: 10.1056/NEJMoa020890. PMID: 12594313.
18. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000 Nov 15;18(22):3809-18. doi: 10.1200/JCO.2000.18.22.3809. PMID: 11078494.